Medicines Optimisation Research and Enterprise Group

Organization profile

Profile Information

Advances in our understanding of pathology and pharmacology have led to an explosion of new medicines in the past 30 years.  Large, biological molecules are now commonplace in the formularies of clinical specialities, and smaller drug compounds which act on a diverse range of targets are providing clinicians and patients with much needed options. 

Yet despite this, medicines, which are the most common therapeutic intervention, carry a risk of harm, and in some patient groups are a significant cause of iatrogenic injury.   There is also a paucity of evidence regarding using medicines simultaneously in patients with multi-morbidity (e.g. the elderly, or new-born infants) as they are not consistently included in clinical trials.  Where data is available, it is interesting to note that there is considerable variation in the therapeutic response patients show to medicines – only some of which we are beginning to understand.  Together, these factors make prescribing complex, and prone to error.

The medicines optimisation research group therefore has three clear goals to improve our understanding of how use medicines safely and effectively:

The science of medicines: Develop world-class research that utilises basic science research expertise and techniques to increase our understanding of medicines.  Areas of research expertise include: pharmacokinetics, pharmacology and microbiology; pharmaceutical formulation; clinical bioanalysis; pharmacogenetics and pharmacogenomics.

The clinical use of medicines: Develop world-class research that examines human behaviours and psychology in health and disease.  Areas of research expertise include: behavioural medicine, health psychology, and paediatrics.

Medicines related education, training and support: Identify and test new approaches to educate and assess the current and future workforce with regards to medicines optimisation, and medicines optimisation research.

Our external partners include, Brighton and Sussex University Hospitals NHS Trust and Brighton and Sussex Medical School

Fingerprint Dive into the research topics where Medicines Optimisation Research and Enterprise Group is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.

  • Network Recent external collaboration on country level. Dive into details by clicking on the dots.


    Research Output

    Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide

    Mabley, J., Patel, J., Sayed, A., Arya, R. & Scutt, G., 12 Feb 2019, In : Thrombosis Research. 176, p. 36-38 3 p.

    Research output: Contribution to journalLetter

    Open Access
  • The periodic table of medicine

    Scutt, G., Okello, A., Scott, R. & Sosabowski, H., 30 Sep 2019, In : School Science Review. 101, 374, p. 71 80 p.

    Research output: Contribution to journalArticle

    Open Access
  • Age-related changes to the expression of nuclear factor erythroid 2-like 2 (Nrf2), a regulatory antioxidant and xenobiotic defence gene

    Scutt, G., Overall, A., Bakrania, P., Krasteva, E., Parekh, N., Ali, K., Davies, G. & Rajkumar, C., 2018, 14th International Congress of the European Geriatric Medicine Society: Advancing Geriatric Medicine in a Modern World. Elsevier, (European Geriatric Medicine).

    Research output: Chapter in Book/Conference proceeding with ISSN or ISBNConference contribution with ISSN or ISBN

  • Activities

    • 1 Invited talk

    DfI: why should I?

    George Olivier (Invited presenter) & Liz Bryant (Invited presenter)

    29 Apr 2018

    Activity: External talk or presentationInvited talk